达格列净联合常规抗心衰药物治疗慢性心力衰竭患者的效果

Effects of Dapagliflozin combined with conventional anti-heart failure drugs in treatment of patients with chronic heart failure

目的:观察达格列净联合常规抗心衰药物治疗慢性心力衰竭(CHF)患者的效果。方法:回顾性分析2020年2月至2022年2月该院收治的67例CHF患者的临床资料,根据治疗方法不同将其分为研究组35例和对照组32例。对照组给予常规抗心衰药物治疗,研究组在对照组基础上联合达格列净片治疗。比较两组临床疗效、治疗前后心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、每搏输出量(SV)、左心室重构指数(LVRI)]水平、心力衰竭标志物[N末端B型利钠肽原(NT-proBNP)、可溶性生长刺激表达基因2蛋白(sST2)、心肌肌钙蛋白I(cTnI)]水平和不良反应发生率。结果:研究组治疗总有效率为94.29%(33/35),高于对照组的71.88%(23/32),差异有统计学意义(P<0.05);治疗后,两组LVEF、SV水平均高于治疗前,且研究组高于对照组,两组LVEDD、LVRI水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组NT-proBNP、sST2、cTnI水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:达格列净联合常规抗心衰药物治疗CHF患者可提高治疗总有效率,改善心功能指标水平,降低心力衰竭标志物水平,其效果优于单纯常规抗心衰药物治疗。

Objective:To observe effects of Dapagliflozin combined with conventional anti-heart failure drugs in treatment of patients with chronic heart failure(CHF).Methods:The clinical data of 67 patients with CHF admitted to this hospital from February 2020 to February 2022 were retrospectively analyzed.According to different treatment methods,they were divided into study group(35 cases)and control group(32 cases).The control group was treated with conventional anti-heart failure drugs,while the study group was treated with Dapagliflozin tablets on the basis of that of the control group.The treatment effects,the cardiac function index levels[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),stroke volume(SV),left ventricular remodeling index(LVRI)],the heart failure marker levels[N-terminal B-type natriuretic peptide(NT-proBNP),soluble growth stimulating gene 2 protein(sST2),cardiac troponin I(cTnI)],and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the study group was 94.29%(33/35),which was higher than 71.88%(23/32)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of LVEF and SV in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the levels of LVEDD and LVRI in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of NT-proBNP,sST2 and cTnI in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Dapagliflozin combined with conventional anti-heart failure drugs in the treatment of the CHF patients can improve the total effective rate of treatment,improve the levels of cardiac function indexes,and reduce the levels of heart failure markers.Moreover,it is superior to single conventional anti-heart failure drugs treatment.